BioMarin Secures Royalties on Ascendis' Yuviwel in Patent Settlement
BioMarin Pharmaceutical (NASDAQ:BMRN) has settled a global patent dispute with Ascendis Pharma (NASDAQ:ASND), securing royalty rights to Ascendis’ growth therapy, Yuviwel. Under the agreement, BioMarin will receive 20% of U.S. net sales and 18% in select international markets from May 2030 on Yuviwel revenue retroactive to its first commercial sale. The settlement resolves ongoing legal proceedings across multiple jurisdictions. The financial impact for BioMarin hinges on whether the royalty income can offset potential cannibalization of Voxzogo, a key product generating $1–$1.05 billion in 2026 sales. Yuviwel’s once-weekly dosing may attract patients who might otherwise use Voxzogo's daily injection format. The agreement also grants BioMarin rights to future indications for Yuviwel and combinations with other drugs, potentially offering upside if Ascendis expands the product line.
